JPH043365B2 - - Google Patents
Info
- Publication number
- JPH043365B2 JPH043365B2 JP59117957A JP11795784A JPH043365B2 JP H043365 B2 JPH043365 B2 JP H043365B2 JP 59117957 A JP59117957 A JP 59117957A JP 11795784 A JP11795784 A JP 11795784A JP H043365 B2 JPH043365 B2 JP H043365B2
- Authority
- JP
- Japan
- Prior art keywords
- japanese
- group
- ginseng
- rats
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000005769 Japanese ginseng Nutrition 0.000 claims description 10
- 241000168720 Panax japonicus Species 0.000 claims description 10
- 235000003174 Panax japonicus Nutrition 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000003908 liver function Effects 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 239000002285 corn oil Substances 0.000 description 11
- 235000005687 corn oil Nutrition 0.000 description 11
- 235000008434 ginseng Nutrition 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- -1 etc. are added Substances 0.000 description 9
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241001063953 Angelica shikokiana Species 0.000 description 1
- DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002045 bergapten Drugs 0.000 description 1
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 229940029982 garlic powder Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59117957A JPS60260520A (ja) | 1984-06-07 | 1984-06-07 | 医薬組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59117957A JPS60260520A (ja) | 1984-06-07 | 1984-06-07 | 医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60260520A JPS60260520A (ja) | 1985-12-23 |
| JPH043365B2 true JPH043365B2 (fr) | 1992-01-23 |
Family
ID=14724425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59117957A Granted JPS60260520A (ja) | 1984-06-07 | 1984-06-07 | 医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60260520A (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000027224A1 (fr) * | 1998-11-11 | 2000-05-18 | Manabu Nomura | Produits alimentaires favorables a la sante |
| JP2014237634A (ja) * | 2013-05-09 | 2014-12-18 | 国立大学法人九州大学 | 抽出方法、抽出物及び製品 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006082743A1 (fr) * | 2005-02-04 | 2006-08-10 | Takara Bio Inc. | Agent therapeutique |
| JP2016172711A (ja) * | 2015-03-16 | 2016-09-29 | 国立大学法人九州大学 | 血液凝固阻害剤及び血液凝固阻害剤の生産方法 |
-
1984
- 1984-06-07 JP JP59117957A patent/JPS60260520A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000027224A1 (fr) * | 1998-11-11 | 2000-05-18 | Manabu Nomura | Produits alimentaires favorables a la sante |
| JP2014237634A (ja) * | 2013-05-09 | 2014-12-18 | 国立大学法人九州大学 | 抽出方法、抽出物及び製品 |
| JP2014237635A (ja) * | 2013-05-09 | 2014-12-18 | 国立大学法人九州大学 | 生産方法及び神経保護剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60260520A (ja) | 1985-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102083661B1 (ko) | 밀크씨슬, 강황, 감초 및 결명자를 포함하는 숙취 해소용 조성물 | |
| WO2008043246A1 (fr) | Composition de médicament pour le traitement du diabète de type 2 et sa néopathie chronique | |
| WO2012023146A1 (fr) | Composition pharmaceutique d'extrait de curcuma reformulé et son procédé de préparation | |
| JP3768795B2 (ja) | キサンチンオキシダーゼ阻害剤 | |
| WO2012090194A2 (fr) | Compositions et méthodes de traitements d'une affection cutanée | |
| CN106822599A (zh) | 一种环草石斛提取物及其抗糖尿病用途 | |
| GB2503628A (en) | Pharmaceutical compostion for controlling blood sugar, blood lipid and body weight | |
| CN101143202B (zh) | 一种对化学性肝损伤具有保护作用的复方口服制剂 | |
| US6329000B1 (en) | Extract of pine needle and the use thereof | |
| Jalili et al. | An overview of therapeutic potentials of Taraxacum officinale (dandelion): A traditionally valuable herb with a reach historical background | |
| CN108143755A (zh) | 一种防治2型糖尿病及其并发症的紫茉莉根总黄酮提取物、及其制备方法与应用 | |
| JP2006036787A (ja) | キサンチンオキシダーゼ阻害剤 | |
| JP4516958B2 (ja) | 抗糖尿病用組成物 | |
| JPH043365B2 (fr) | ||
| JP6369931B2 (ja) | 抗肥満剤 | |
| CN1762341B (zh) | 治疗心脑血管疾病、肝脏疾病的丹参酚酸复合物及其应用 | |
| JP3204348B2 (ja) | 動脈硬化抑制剤及びこれを含む食品又は医薬 | |
| JP3549997B2 (ja) | リパーゼ阻害効果を有する食品組成物および医薬組成物 | |
| JP4601069B2 (ja) | 高脂血症治療のための相乗効果的医薬組成物 | |
| JP2001261569A (ja) | 抗肥満症剤 | |
| JP3142192B2 (ja) | 血中脂質改善剤及びこれを含有する組成物 | |
| JP4610730B2 (ja) | カルシウム補給用の組成物 | |
| JP2000072685A (ja) | 消化器潰瘍を抑制するための食品および医薬組成物 | |
| JP3183758B2 (ja) | 血中中性脂肪改善剤及びその製造方法並びにこれを含有する組成物 | |
| JP3183754B2 (ja) | 動脈硬化抑制剤及びこれを含有する組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |